Cargando…
Xin-Li-Fang efficacy and safety for patients with chronic heart failure: A study protocol for a randomized, double-blind, and placebo-controlled trial
INTRODUCTION: Xin-Li-Fang (XLF), a representative Chinese patent medicine, was derived from years of clinical experience by academician Chen Keji, and is widely used to treat chronic heart failure (CHF). However, there remains a lack of high-quality evidence to support clinical decision-making. Ther...
Autores principales: | Liu, Tong, Yao, Sijie, Jiang, Wei, Lan, Taohua, Xu, Wenjing, Cao, Haiming, Yao, Ping, Wang, Chao, Lu, Weihui, Chen, Xiankun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911457/ https://www.ncbi.nlm.nih.gov/pubmed/36776264 http://dx.doi.org/10.3389/fcvm.2023.1103548 |
Ejemplares similares
-
Xin-Li formula attenuates heart failure induced by a combination of hyperlipidemia and myocardial infarction in rats via Treg immunomodulation and NLRP3 inflammasome inhibition
por: Lan, Taohua, et al.
Publicado: (2023) -
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016) -
Feasibility and Preliminary Effects of the BESMILE-HF Program on Chronic Heart Failure Patients: A Pilot Randomized Controlled Trial
por: Chen, Xiankun, et al.
Publicado: (2021) -
Metabolism disorder promotes isoproterenol-induced myocardial injury in mice with high temperature and high humidity and high-fat diet
por: Lan, Taohua, et al.
Publicado: (2022) -
Bushen Yijing Fang Reduces Fall Risk in Late Postmenopausal Women with Osteopenia: A Randomized Double-blind and Placebo-controlled Trial
por: Zheng, Yuxin, et al.
Publicado: (2019)